Off-label stent use: DES associated with equal safety risks and reduced risk of repeat PCI compared with BMS
Study shows no significant differences in safety risks between off-label use of drug-eluting stents (DES) and off-label use of bare-metal stents (BMS) and a decreased risk of repeat PCI with use of off-label BMS.
In a new, large database study that evaluated 6,551 patients from the National Heart, Lung, and Blood Institute (NHLBI) Dynamic Registry, the use of drug-eluting stents (DES) for off-label indications was associated with a lower risk of repeat revascularization without any excess risk of death or myocardial infarction (MI) compared with the off-label use of bare-metal stents (BMS). The study was published in the New England Journal of Medicine (NEJM).
Off-label stent use was defined as use in lesions in a bypass graft; left main coronary artery disease; restenotic lesions; or ostial, bifurcated, or totally occluded lesions, and in patients with a reference-vessel diameter <2.5 mm or >3.75 mm or a lesion length >30 mm. Off-label use occurred in 54.7% of registered patients who received BMS and in 48.7% of patients who received DES.
At 1 year, the adjusted risk of repeat percutaneous coronary intervention (PCI) was significantly lower among patients who received off-label DES compared with those who received off-label BMS (adjusted HR=0.75; 95% CI, 0.61–0.93). The adjusted risk of repeat revascularization was also lower among patients who received DES compared with those who received BMS (adjusted HR=0.63; 95% CI, 0.52–0.77). These reduced risks were demonstrated consistently in most subgroups of patients who received off-label DES versus those who received off-label BMS.
The authors stated that these data support off-label use of DES.
In an accompanying editorial, Joseph Carrozza, Jr, MD, emphasized that studies such as this one go a long way towards making the decision to use stents for these off-label indications more evidence based; however, Dr Carrozza cautioned that additional studies, ideally with a randomized trial design, are still needed to definitively support the off-label use of DES.
SOURCES
Marroquin OC, Selzer F, Mulukutla SR, et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med. 2008;358:342–352.
Carrozza JP Jr. Drug-eluting stents - pushing the envelope beyond the labels [editorial]? N Engl J Med. 2008;358:405–407.
FDA Issues Complete Response Letter for Onpattro in Heart Failure Indication
October 9th 2023Alnylam Pharmaceuticals will no longer pursue this indication of Onpattro and will instead on focus on a label expansion for Amvuttra, which is in phase 3 development to treat patients with cardiomyopathy of ATTR amyloidosis.
FDA Advisory Committee Backs Use of Onpattro in Heart Failure Indication
September 16th 2023Even though committee members voted in support of Onpattro for patients with cardiomyopathy related to transthyretin-mediated amyloidosis, there were questions about whether it provided a clinically meaningful benefit. The FDA set an action date of Oct. 8, 2023.
